1 / 58

Pancreatic cancer

Pancreatic cancer. WU JIAN Department of hepatobiliary Surgery First Affiliated Hospital Zhejiang University School of Medicine. INTRODUCTION. Significant increase Difficult early diagnosis, difficult surgical resection poor prognosis 90 ％ patients die within 1 year after diagnosis

finn
Télécharger la présentation

Pancreatic cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pancreatic cancer WU JIAN Department of hepatobiliary Surgery First Affiliated Hospital Zhejiang University School of Medicine

  2. INTRODUCTION • Significant increase • Difficult early diagnosis, difficult surgical resection poor prognosis • 90％ patients die within 1 year after diagnosis • 5 year survival rate 1％－3％ (lowest in malignancy) • Common in pancreatic head，about 2/3

  3. INTRODUCTION • Ductal Adenocarcinoma accounts for about 90％of pancreatic neoplasms, • At the time of diagnosis more than 85 per cent of these tumours have extended beyond the limits of the organ • Perineural invasion • Lymphatic spread • Extralymphatic involvement are the liver and peritoneum.

  4. Manifestation of Pancreatic Cancer • Pain or fullness in epigastrium • Jaundice, itchy • Dark urine, light stool • weight loss, fatigue • GI symptom • Others • Diabetes mellitus • An episode of acute pancreatitis

  5. Physical Signs • Jaundice • Non-tender gallbladder (Courvoisier's sign ) • In advanced disease ( indicative of an unresectable tumour ) • Ascites • Palpable mass.

  6. Strong Suspicion of Pancreatic Cancer • Pain in epigastrium or back in recent two years • Recent GI symptom, negative GI test • Obstructive jaundice • Unexplained weight loss • Unexplained pancreatitis • Unexplained diabetes mellitus

  7. Serum Tumor Marker • CA199, CA50, CEA , CA242, PCAA, PaA, SPAN-1 Dupan for markers • K-ras gene • Poor sensitivity and specificity • Combined test

  8. Image findings • Ultrasonography • Computerized tomography (CT)/spiral CT • Magnetic resonance imaging (MRI) • has no advantage over CT • Endoscopic ultrasonography • Endoscopic retrograde cholangiopancreatography (ERCP) Magnetic resonance cholangiopancreatography (MRCP) • Percutaneous transhepatic cholangiography (PTC) • Angiography • Positron Emission Tomography(PET)

  9. CT

  10. CT

  11. CT

  12. MRCP

  13. MRCP

  14. Patient 1

  15. Patient 1

  16. Patient 1

  17. Patient 2

  18. Patient 2

  19. Patient 2

  20. Patient 2

  21. Endoscopy • ERCP • Cytology in Pancreatic juice • Tumor marker • Gene detection

  22. Combination between Endoscope and Ultrasonography • Endoscopic US (EUS) • Intra-duct US (IDUS)

  23. Treatment • Radical resection is the only effective therapy option • pancreatoduodenectomy • Cholecystojejunostomy, choledochojejunostomy • Gastrojejunostomy • Chemotherapy • Radiotherapty • Gene therapy • Immnotherapy

  24. Radical Resection • Pancreatoduodenectomy（PD） • Whipple operation • Child operation • Total pancreatectomy • Regional pancreatectomy • Pylorus-preserving pancreatoduodenectomy (PPPD)

  25. P 656

  26. Operation Choice • Regional pancreatectomy • Severe operation trauma • Result is not confirmed • Remain to be verify • PPPD • Stomach is preserved • LN around pylorus can not be resected • Mainly in ampullary tumor

  27. Common Point • Basic operation: PD • Standard operation: PD + D2 lymphadenectomy • Cancer invades to vessel resection of portal vein or SMA

  28. Palliative Procedures • Biliary or GI obstruction • Ameliorate the quality of survival • Not elevate survival rate • Operation methods • Choledochojejunostomy • Gastrojejunostomy • Jejunojejunostomy • Gastrojejunostomy

  29. choledochojejunostomy gastrojejunostomy

  30. Microinvasive Surgery • Relieve pain, reduce hospital time, reduce hospital charge • Procedure • Endoscopic stenting • Percutaneous stent • Gastrojejunostomy under laparoscopy

  31. Chemotherapy

  32. Gene Therapy

  33. Periampullary Cancer • Lower part of CBD, ampulla, papila • High frequency of intestinal bleeding • Fluctuation of jaundice • ERCP are the mainstays in differentiation • Result is much better

  34. Endocrine tumor in pancreas • B cell，insulin，insulinoma • G cell，gastrin，gastrinoma • D1 cell，vasoactive intestinal peptide(VIP) VIPoma • A cell，glucagon，glucagonoma • D cell，somatostatin， somatostatinoma

  35. Insulinoma

  36. Most common endocrinal tumor in pancreas , 75% • Acute attack • Long disease development

  37. Clinical Manifestation • Typical Whipple Triad • Hypoglycemia symptom after fasting or work • glucose <2.8mmol/L • Symptom relieves after administration of glucose by oral or vein

  38. Hypoglycemia Symptom • Sympathetic symptom • Pale, sweat, quick HB • Psychiatric symptom • Faintness , dullness, coma • Degenerative change of brain • Confusion, disorder behavior, low intelligence

  39. Laboratory test • Fasting blood sugar(FBS) • Immunoreactive insulin (IRI） > 25U/ml • Oral glucose tolerance test (OGTT) • Insulin release test（IRI/G）> 0.3

  40. image finding • BUS • CT • Selective angiography, • Intraoperative ultrasonography（ IOUS） • Sensitivity nearly 100％ • Laparotomy

More Related